Skip to Main Content

WASHINGTON — The fate of the Democratic party’s ambitious goal of allowing Medicare to negotiate drug prices rests with a handful of key moderate senators.

Negotiations on the exact scope of the reforms heated up this week after months of stalemate. But as lawmakers push to compile an outline of the massive domestic spending package that forms a cornerstone of President Biden’s domestic agenda, solid consensus on drug pricing policies has proved elusive.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment